Nebivolol Almus (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors on the heart, decreasing heart rate and contractility. It also stimulates endothelial nitric‑oxide synthase, leading to increased nitric‑oxide release and vasodilation of peripheral vessels, which together lower systemic vascular resistance and blood pressure.

The appropriate dose of Nebivolol Almus is determined by the prescribing healthcare professional based on the patient’s condition, response, and other clinical factors. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of nebivolol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nebivolol Almus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol differs from many traditional beta‑blockers by also enhancing nitric‑oxide‑mediated vasodilation, which can improve endothelial function and cause fewer metabolic side effects. This dual mechanism may offer better tolerability for some patients, though clinical choice depends on individual patient profiles and physician judgment.

Nebivolol Almus should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Nebivolol Almus is taken orally, usually as a tablet, with or without food as directed by the prescriber. The medication should be swallowed whole with a glass of water, and patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include severe bradycardia, heart block, and marked hypotension, which may lead to fainting or cardiovascular collapse. Patients should be monitored for these events, especially when initiating therapy or when combined with other drugs that affect heart rate or blood pressure.

Nebivolol Almus should be avoided in patients with known hypersensitivity to nebivolol or any excipients, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure unless specifically prescribed by a specialist.